Kamada
$ 8.44
0.24%
15 Apr - close price
- Market Cap 486,811,000 USD
- Current Price $ 8.44
- High / Low $ 8.45 / 8.35
- Stock P/E 24.06
- Book Value 4.66
- EPS 0.35
- Next Earning Report 2026-05-13
- Dividend Per Share $0.25
- Dividend Yield 2.97 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.08 %
- 52 Week High 9.07
- 52 Week Low 6.16
About
Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel.
Analyst Target Price
$13.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-18 | 2025-11-10 | 2025-08-13 | 2025-05-06 | 2025-03-04 | 2024-11-11 | 2024-08-14 | 2024-05-08 | 2024-03-06 | 2023-11-13 | 2023-08-16 | 2023-05-24 |
| Reported EPS | 0.06 | 0.29 | 0.19 | 0.07 | 0.07 | 0.07 | 0.08 | 0.04 | 0.09 | 0.06 | 0.04 | -0.04 |
| Estimated EPS | 0.1 | 0.09 | 0.08 | 0.0675 | 0.0533 | 0.07 | 0.06 | 0.06 | 0.05 | 0.03 | 0.02 | 0.03 |
| Surprise | -0.04 | 0.2 | 0.11 | 0.0025 | 0.0167 | 0 | 0.02 | -0.02 | 0.04 | 0.03 | 0.02 | -0.07 |
| Surprise Percentage | -40% | 222.2222% | 137.5% | 3.7037% | 31.3321% | 0% | 33.3333% | -33.3333% | 80% | 100% | 100% | -233.3333% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.12 |
| Currency | USD |
Previous Dividend Records
| Apr 2026 | Apr 2025 | |
|---|---|---|
| Payment Date | 2026-04-07 | 2025-04-07 |
| Amount | $0.25 | $0.2 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KMDA
2026-04-10 16:09:17
Kamada Ltd. director David Tsur reported adjustments to employee stock option awards through a trustee, following a cash dividend declared by the company's board. These routine changes, which are not open-market trades, involve multiple grant acquisitions and dispositions, with exercise prices adjusted due to the dividend. The options, which vest in four equal annual installments, have expiration dates in 2026 and 2029 and are held under Kamada's 2011 Share Award Plan.
2026-04-10 16:09:16
Kamada's VP of Operations, Nir Eran, reported adjustments to his compensation-related employee stock options. On April 7, 2026, he received grants for 112,500 Employee Stock Options to buy Ordinary Shares and simultaneously surrendered an equal number of options back to the company under the 2011 Share Award Plan. These adjustments, including revised exercise prices due to a cash dividend distribution, are outlined in a Form 4 SEC filing, indicating no open-market transactions.
2026-04-10 14:40:23
Assaf Itshayek, a Director at Kamada (NASDAQ: KMDA), acquired stock options for 16,000 shares worth $41,280, signaling potential future growth in the company. Kamada has shown strong revenue growth of 14.54% as of December 31, 2025, and maintains a sound financial structure with a low debt-to-equity ratio. However, the company faces challenges with a low gross margin and an EPS trailing industry averages, and its stock appears overvalued based on P/E and P/S ratios.
2026-04-10 14:40:23
Amir London, CEO of Kamada (NASDAQ: KMDA), acquired stock options for 800,000 shares worth $1.56 million on April 9th. This insider move, coupled with Kamada's positive revenue growth of 14.54% and low debt-to-equity ratio, suggests a bullish outlook despite profitability metrics and valuation ratios indicating potential overvaluation. Insider transactions are viewed as a positive signal, but investors are advised to consider them alongside other financial factors.
2026-04-10 14:40:23
Eran Nir, VP at Kamada (NASDAQ: KMDA), acquired stock options for 112,500 shares valued at $178,425, signaling optimism for the company's future growth. The article also details Kamada's financial performance, including a 14.54% revenue growth as of December 31, 2025, but notes challenges such as a low gross margin and high P/E ratio. Insider transactions are highlighted as a key indicator for investors, pointing to management's positive outlook.
2026-04-10 03:39:49
This page provides access to Kamada Ltd.'s (KMDA) SEC filings, including 10-K, 10-Q, 8-K, and Form 6-K reports, which detail financial results, operational milestones, and strategic initiatives. Recent filings highlight record 2025 results, a new dividend policy, 2026 growth guidance, and clinical trial updates. It serves as a comprehensive resource for investors to track the company's performance and regulatory disclosures.
